Compounds and compositions for intracellular delivery of therapeutic agents

Patent metadata

Field	Value
Publication number	US-12151995-B2
Application number	US-202318467190-A
Country	US
Kind code	B2
Filing date	Sep 14, 2023
Priority date	Sep 17, 2015
Publication date	Nov 26, 2024
Grant date	Nov 26, 2024

Abstract

The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

First claim

The invention claimed is:

1. A compound of Formula (I):

or salts or isomers thereof, wherein:
R 1 is —R″M′R′ or C 5-20 alkenyl;
R 2 and R 3 are each independently selected from C 1-14 alkyl and C 2-14 alkenyl;
R 4 is —(CH 2 ) n Q, wherein Q is OH and n is selected from 3, 4, and 5;
M and M′ are each independently —C(O)O— or —OC(O)—;
R 5 , R 6 , and R 7 are each H;
R′ is a linear C 1-12 alkyl, or C 1-12 alkyl substituted with C 6-9 alkyl;
R″ is C 3-14 alkyl;
m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13.

2. The compound of claim 1 , wherein n is 3 or 4.

3. The compound of claim 1 , wherein R 2 and R 3 are each independently C 6-8 alkyl.

4. The compound of claim 3 , wherein R 2 and R 3 are the same.

5. The compound of claim 3 , wherein R 2 and R 3 are different.

6. The compound of claim 1 , wherein R′ is C 6-9 alkyl substituted with C 6-9 alkyl.

7. The compound of claim 1 , wherein R′ is a linear C 6-9 alkyl.

8. The compound of claim 1 , wherein the compound is selected from:

9. A compound of Formula (I):

or salts or isomers thereof, wherein:
R 1 is —R″M′R′ or C 5-20 alkenyl;
R 2 and R 3 are each independently selected from C 1-14 alkyl and C 2-14 alkenyl;
R 4 is —(CH 2 ) n Q, wherein Q is OH and n is selected from 1, 2, 3, 4, and 5;
M and M′ are each independently —C(O)O— or —OC(O)—;
R 5 , R 6 , and R 7 are each H;
R′ is a linear C 1-12 alkyl, or C 1-12 alkyl substituted with C 6-9 alkyl;
R″ is C 6-14 alkyl;
m is selected from 6, 7, 8, 9, 10, 11, 12, and 13.

10. The compound of claim 9 , wherein n is 2, 3, or 4.

11. The compound of claim 9 , wherein R″ is C 6-9 alkyl.

12. The compound of claim 9 , wherein m is selected from 6, 7, 8, and 9.

13. The compound of claim 9 , wherein R 2 and R 3 are each independently C 6-8 alkyl.

14. The compound of claim 13 , wherein R 2 and R 3 are the same.

15. The compound of claim 13 , wherein R 2 and R 3 are different.

16. The compound of claim 9 , wherein R′ is C 6-9 alkyl substituted with C 6-9 alkyl.

17. The compound of claim 9 , wherein R′ is a linear C 6-9 alkyl.

18. The compound of claim 9 , wherein the compound is selected from:

19. A compound of Formula (IA):

or a salt or isomer thereof, wherein
l is selected from 1, 2, 3, 4, and 5;
m is selected from 5, 6, 7, 8, and 9;
M 1 is a bond or M′;
R 4 is unsubstituted C 1-3 alkyl, or —(CH 2 ) n Q, in which Q is OH, —NHC(S)N(R) 2 , —NHC(O)N(R) 2 , —N(R)C(O)R, —N(R)S(O) 2 R, —N(R)R 8 , —NHC(═NR 9 )N(R) 2 , —NHC(═CHR 9 )N(R) 2 , —OC(O)N(R) 2 , —N(R)C(O)OR, —N(OR)C(O)R, —N(OR)S(O) 2 R, —N(OR)C(O)OR, —N(OR)C(O)N(R) 2 , —N(OR)C(S)N(R) 2 , —N(OR)C(═NR 9 )N(R) 2 , —N(OR)C(═CHR 9 )N(R) 2 , or heteroaryl, and each n is selected from 1, 2, 3, 4, or 5;
M and M′ are independently selected

from —C(O)O—, —OC(O)—, —C(O)N(R′)-, —P(O)(OR′)O-,
—S—S—, an aryl group, and a heteroaryl group; and
R 2 and R 3 are both C 1-14 alkyl, or C 2-14 alkenyl;
R 8 is selected from the group consisting of C 3-6 carbocycle and heterocycle;
R 9 is selected from the group consisting of H, CN, NO 2 , C 1-6 alkyl, —OR, —S(O) 2 R, —S(O) 2 N(R) 2 , C 2-6 alkenyl, C 3-6 carbocycle and heterocycle;
each R is independently selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H; and
R′ is a linear alkenyl.

20. A nanoparticle composition comprising a lipid component comprising a compound of claim 1 .

21. The nanoparticle composition of claim 20 , wherein the lipid component further comprises a phospholipid, wherein the phospholipid is selected from the group consisting of 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine,1,2-dioleoyl-sn-glycero-3-phosphoethanola mine (DOPE), 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0 PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), dipalmitoylphosphatidylglycerol (DPPG), palmitoyloleoylphosphatidylethanolamine (POPE), distearoyl-phosphatidyl-ethanolamine (DSPE), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), 1-stearoyl-2-oleoyl-phosphatidyethanolamine (SOPE), 1-stearoyl-2-oleoyl-phosphatidylcholine (SOPC), sphingomyelin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleoyl phosphatidylcholine, lysophosphatidylcholine, lysophosphatidylethanolamine (LPE), and mixtures thereof.

22. The nanoparticle composition of claim 20 , wherein the lipid component further comprises a structural lipid, wherein the structural lipid is selected from the group consisting of cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, alpha-tocopherol, and mixtures thereof.

23. The nanoparticle composition of claim 20 , wherein the lipid component further comprises a PEG lipid, wherein the PEG lipid is selected from the group consisting of a PEG-modified phosphatidylethanolamine, a PEG-modified phosphatidic acid, a PEG-modified ceramide, a PEG-modified dialkylamine, a PEG-modified diacylglycerol, a PEG-modified dialkylglycerol, and mixtures thereof.

24. The nanoparticle composition of claim 20 , further comprising a therapeutic and/or prophylactic agent.

25. The nanoparticle composition of claim 24 , wherein the therapeutic and/or prophylactic agent is a nucleic acid.

26. A nanoparticle composition comprising a lipid component

Assignees

• Modernatx Inc

Inventors

• Benenato Kerry E
• Cornebise Mark
• Kumarasinghe Ellalahewage Sathyajith

Classifications

• C07C227/18

  by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters · CPC title

• A61K48/0033

  the non-active part being non-polymeric · CPC title

• A61K38/1725

  Complement proteins, e.g. anaphylatoxin, C3a or C5a · CPC title

• A61K31/7105

  Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links · CPC title

• A61K9/5146

  obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides · CPC title